News
1 in 5 respondents either have had or do have a fractional role, according to a recent BioSpace poll, and over half are considering it. Two recruitment experts, a fractional worker and an aspiring fractional worker share their insights.
FEATURED STORIES
Disruptive conditions are typical in non-Western markets. The U.S. industry, thrown into a period of significant change as the Trump administration overhauls HHS and considers implementing tariffs, could learn a thing or two by looking overseas.
Like they say about the weather in Iceland, if you donât like an action taken by the new administration, wait five minutes; itâll probably change. The markets, it seems, donât react kindly to that kind of policymaking.
Analysts have had to throw out their assumptions for the biopharma industryâs recovery heading into the first quarter earnings period given the ongoing tariff drama.
Job Trends
Bio-Techne Corporation is pleased to announce a significant milestone in its commitment to providing cutting-edge solutions to its customers.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
During the COVID-19 pandemic, Health Secretary Robert F. Kennedy Jr.âalong with FDA Commissioner Marty Makary and CBER Director Vinay Prasadâargued against vaccine mandates, partly because they limited medical choice. This week, the FDA under their leadership approved updated COVID-19 vaccines with restrictions that do the same.
THE LATEST
Industry watchers responded mostly positively to the commissionerâs new voucher program, but worries remain over staffing cuts at the agency.
The U.K.-based biotech is set to enter mid-stage studies for its depression drug this year, while two other GABAA modulators are poised for clinical trials in 2026.
Speaking at BIO2025, Makary bemoaned what he called âunnecessary stepsâ and âavoidable delaysâ in the U.S. regulatory landscape.
The new version of the bill will still need to go through the entire House and Senate.
Andembry is the first monthly Factor XIIa inhibitor for the prevention of HAE attacks and will be available to patients âbefore the end of June,â CSL announced.
Another patient has died from acute liver failure after receiving Sareptaâs gene therapy for DMD ; After a quiet start to the year, M&A is back with one deal for a gene editing biotech reinvigorating that sector; and RFK Jr. installs a suite of new vaccine board members who share his skeptical views on vaccines.
Findings that U.S. companies can sue foreign rivals despite limited business operations in the country could dissuade drug developers from targeting the U.S. market, potentially benefiting domestic producers of biosimilars.
BioNTech said in 2022 that it faced âthreats of a groundless patent infringement suitâ from a company that was âunable to bring to market any product to help in the fight against COVID-19.â Now, the mRNA biotech is buying that very company.
Sanofi paid a more than 300% premium on its acquisition of Vigil Neuroscience, suggesting a fierce battle to seal the deal. Across biopharma, companies are sometimes willing to put it all on the line for the right buyout. Novartisâ recent acquisition of Regulus for $800 million upfront provides a case study.
The program will bring together experts from across the FDA for a team-based review, rather than having an application move across numerous offices within the agency before getting a yay or nay.